Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
-
Patent number: 11970495Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.Type: GrantFiled: April 10, 2023Date of Patent: April 30, 2024Assignee: KIND PHARMACEUTICALInventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
-
Patent number: 11969397Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.Type: GrantFiled: November 7, 2019Date of Patent: April 30, 2024Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Dong-Yun Shin, Jong-Young Choi, Chul-Woo Yang, Sung-Hwan Park, Seon-Yeong Lee, Min-Jung Park, Joo-Yeon Jhun, Se-Young Kim, Hyeon-Beom Seo, Jae-Yoon Ryu, Keun-Hyung Cho
-
Patent number: 11957666Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.Type: GrantFiled: September 14, 2021Date of Patent: April 16, 2024Assignee: VELOXIS PHARMACEUTICALS, INC.Inventor: William J. Polvino
-
Patent number: 11945817Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.Type: GrantFiled: April 10, 2023Date of Patent: April 2, 2024Assignee: KIND PHARMACEUTICALInventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
-
Patent number: 11919912Abstract: Provided are novel compounds of Formula (I): Formula (I); and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.Type: GrantFiled: May 17, 2019Date of Patent: March 5, 2024Assignee: Constellation Pharmaceuticals, Inc.Inventors: Alexandre Côté, Avinash Khanna, Ludivine Moine
-
Patent number: 11903851Abstract: A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold.Type: GrantFiled: August 12, 2020Date of Patent: February 20, 2024Assignee: Q3 MEDICAL DEVICES LIMITEDInventor: Eric K. Mangiardi
-
Patent number: 11866437Abstract: Novel 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: September 15, 2023Date of Patent: January 9, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11833147Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: January 8, 2021Date of Patent: December 5, 2023Assignees: Vanquish Oncology, Inc., The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 11826465Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.Type: GrantFiled: May 10, 2022Date of Patent: November 28, 2023Assignee: CMPD Licensing, LLCInventor: Jay Richard Ray, II
-
Patent number: 11759810Abstract: A refill device for a container having an opening to a cavity including a first connection element with first connection means for removably connecting the refill device to the opening, a bag first part filled with a substance for housing in the container, a neck and a connection part between the neck and the first part, and a flange, a pump, a ring nut element connected to the first connection element to connect the pump and bag thereto, the first connection element including a body with an upper part including an upper opening delimited by a wall for resting a portion of the flange and connection means, a lower part including an opening and first means for removably connecting the refill device, the first connection element including second connection means for removably connecting a protection element to the first connection element before associating the refill device with the container.Type: GrantFiled: July 8, 2022Date of Patent: September 19, 2023Assignee: LUMSON S.P.A.Inventor: Matteo Moretti
-
Patent number: 11717569Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.Type: GrantFiled: February 22, 2016Date of Patent: August 8, 2023Assignee: Selecta Biosciences, Inc.Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
-
Patent number: 11654036Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.Type: GrantFiled: August 13, 2021Date of Patent: May 23, 2023Assignee: Elixir Medical CorporationInventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
-
Patent number: 11655249Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.Type: GrantFiled: April 23, 2021Date of Patent: May 23, 2023Assignee: KIND PHARMACEUTICALInventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
-
Patent number: 11541040Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.Type: GrantFiled: August 21, 2019Date of Patent: January 3, 2023Inventor: Koushi Yamaguchi
-
Patent number: 11419823Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.Type: GrantFiled: November 13, 2018Date of Patent: August 23, 2022Assignee: VELOXIS PHARMACEUTICALS, INC.Inventors: Nikolaj Skak, Per Holm
-
Patent number: 11351120Abstract: The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.Type: GrantFiled: November 19, 2019Date of Patent: June 7, 2022Assignee: Supernus Pharmaceuticals, Inc.Inventors: Stephen D. Collins, Peter J. Goldstein, Joshua T. Johnstone
-
Patent number: 11343914Abstract: An electronic device is provided. The electronic device includes a conductive support member, a first circuit board connected to the conductive support member by a first capacitor, a second circuit board connected to the conductive support member by a second capacitor, a first conductive connection member electrically connecting the first circuit board and the second circuit board, and a first ground structure, at least a portion of the first ground structure being interposed between the first conductive connection member and the conductive support member. The ground structure includes a non-conductive layer physically contacting the conductive support member, and a conductive layer electrically connected to the first conductive connection member to form a capacitive coupling with the conductive support member.Type: GrantFiled: February 21, 2019Date of Patent: May 24, 2022Assignee: Samsung Electronics Co., Ltd.Inventors: Wangik Son, Minho Kim, Sunghyun Kim, Eungwon Kim, Chanbeom Jeong
-
Patent number: 11285116Abstract: Recently, we have introduced fibrous dosage forms that enable predictable microstructures with a greater range of pharmaceutically relevant properties. Presented herein, accordingly, is a method for the manufacture of such fibrous dosage forms. The method includes extruding a plasticized matrix through an exit port of an extrusion channel to form one or more plasticized fibers, structuring said fibers to a three dimensional structural network by patterning on a translating or rotating stage, and solidifying the patterned structure.Type: GrantFiled: April 28, 2020Date of Patent: March 29, 2022Inventor: Aron H. Blaesi
-
Patent number: 11285081Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.Type: GrantFiled: February 14, 2018Date of Patent: March 29, 2022Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Sreenivasu Mudumba, Kedar Datar, Hiromitsu Shiono, Chun-jung Chu, Le An, Sudeep Rauser
-
Patent number: 11208475Abstract: The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators, such as serotonin receptor activating antibodies, among others. The invention also features compositions containing serotonin receptor activators, methods of diagnosing patients with a serotonin receptor-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with serotonin receptor activators.Type: GrantFiled: January 30, 2019Date of Patent: December 28, 2021Assignee: Flagship Pioneering Innovations V, Inc.Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
-
Patent number: 11179374Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.Type: GrantFiled: May 21, 2020Date of Patent: November 23, 2021Assignee: Drexel UniversityInventors: Christian Sell, Timothy Nacarelli, Ashley Azar
-
Patent number: 11103449Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.Type: GrantFiled: July 23, 2018Date of Patent: August 31, 2021Assignee: AI Therapeutics, Inc.Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
-
Patent number: 11021478Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.Type: GrantFiled: May 8, 2018Date of Patent: June 1, 2021Assignee: KIND PHARMACEUTICALInventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
-
Patent number: 11020486Abstract: Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.Type: GrantFiled: October 30, 2014Date of Patent: June 1, 2021Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Joseph M. Beaurline, James M. Elvecrog, John P. Vasilakos, John Thomas Capecchi, Karen Elizabeth Johnson
-
Patent number: 10844436Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.Type: GrantFiled: April 1, 2015Date of Patent: November 24, 2020Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Jacqueline Bromberg
-
Patent number: 10835553Abstract: The invention discloses an application of hydroxypropyl methyl cellulose in preparation of medicines for treating esophageal mucosa. The invention discloses a hydroxypropyl methyl cellulose-containing composition which comprises the following ingredients: 1-28 weight parts of hydroxypropyl methyl cellulose and 1000 weight parts of purified water. A preparation method includes steps of adding the hydroxypropyl methyl cellulose, by stirring, into the purified water in an amount which accounts for 40% of the total amount of water used to obtain a mixed material, continuously stirring the mixed material until the mixed material is completely swelling and turning into a transparent solution, adding the remaining purified water to obtain a mixture, and stirring the mixture to obtain the hydroxypropyl methyl cellulose-containing composition.Type: GrantFiled: January 14, 2019Date of Patent: November 17, 2020Assignee: Hefei Jiuyan Pharmaceutical Science and Technology Development Co., Ltd.Inventors: Yu Gao, Yunli Bu
-
Patent number: 10813890Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.Type: GrantFiled: August 10, 2017Date of Patent: October 27, 2020Assignee: Grünenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke
-
Patent number: 10711020Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: March 7, 2019Date of Patent: July 14, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Robert J. Cherney
-
Patent number: 10695327Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: October 8, 2018Date of Patent: June 30, 2020Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10688085Abstract: Provided are a pharmaceutical composition exhibiting therapeutic efficacy against EML4-ALK-positive non-small cell lung cancer that has acquired resistance to an ALK inhibitor and a method for treating the non-small cell lung cancer. Further, provided is information for drug selection for determining whether to administer a statin-based drug to a patient group with EML4-ALK-positive non-small cell lung cancer.Type: GrantFiled: January 13, 2017Date of Patent: June 23, 2020Assignees: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY, JEUK CO., LTD.Inventors: Kyoung-Je Cho, Byoung Chul Cho, Mi-Ran Yun, Kyoung-Ho Pyo, Han Na Kang, Hun-Mi Choi
-
Patent number: 10634668Abstract: Methods of reversibly inducing proximity of first and second target molecules in a sample are provided. Aspects of the methods include contacting the sample with a modifiable chemical inducer of proximity (MCIP) that reversibly induces proximity of the first and second target molecules, upon application of a stimulus that modifies the MCIP. Aspects of the invention further include methods for regulating a biological process in a cell. Aspects of the invention further include compositions, e.g., compounds and kits, etc., that find use in methods of the invention.Type: GrantFiled: September 10, 2013Date of Patent: April 28, 2020Assignee: TAKARA BIO USA, INC.Inventors: Eric Espinosa, Andrew Farmer
-
Patent number: 10632108Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.Type: GrantFiled: May 7, 2018Date of Patent: April 28, 2020Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas R. Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
-
Patent number: 10624884Abstract: The present invention concerns the use of an H4 agonist molecule against histamin, enantiomers of (AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2 METHYLENEDIOXY-6,7 TETRAHYDRO-,2,3,4 ISOQUINOLINE or tritoqualine, for the treatment of idiopathic pulmonary fibrosis.Type: GrantFiled: May 2, 2019Date of Patent: April 21, 2020Assignee: H4 ORPHAN PHARMAInventors: Gaëtan Terrasse, Catherine Bur
-
Patent number: 10617678Abstract: Described herein are methods for distributing temsirolimus to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of temsirolimus for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: February 7, 2018Date of Patent: April 14, 2020Assignee: MERCATOR MEDSYSTEMS, INC.Inventor: Kirk Patrick Seward
-
Patent number: 10596107Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.Type: GrantFiled: January 26, 2016Date of Patent: March 24, 2020Assignee: Bausch & Lomb IncorporatedInventors: Mohannad Shawer, Eric Phillips, Martin J. Coffey
-
Patent number: 10576063Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.Type: GrantFiled: May 25, 2018Date of Patent: March 3, 2020Assignee: Mercator MedSystems, Inc.Inventor: Kirk Patrick Seward
-
Patent number: 10548861Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.Type: GrantFiled: August 17, 2016Date of Patent: February 4, 2020Assignees: Academia Sinica, Memorial Sloan Kettering Cancer CenterInventors: Malcolm Moore, Jae-Hung Shieh, Tsann-Long Su, Te-Chang Lee
-
Patent number: 10492356Abstract: The invention encompasses a nontoxic agricultural formulation of a concentrated liquid suspension comprising an organic phase and suspended particulate materials, and also encompasses an aqueous formulation comprising the concentrated liquid suspension and an agricultural treatment agent. The invention additionally encompasses methods of treating an agricultural target, comprising providing an agricultural formulation of a concentrated liquid suspension comprising an organic phase and suspended particulates, and applying the agricultural formulation onto the agricultural target, thereby treating the agricultural target.Type: GrantFiled: July 5, 2017Date of Patent: December 3, 2019Assignee: CROP ENHANCEMENT, INC.Inventors: Jonathan Flores, Matthew A. Bosley, Sandra Rifai, Robert P. Mahoney, Damian Hajduk, Rosa Casado Portilla, Turner Newton, David S. Soane
-
Patent number: 10456383Abstract: Methods are provided for the targeted treatment of Epidermolysis Bullosa simplex.Type: GrantFiled: May 31, 2018Date of Patent: October 29, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Joyce Teng, Heather Irina Rishel, Dédée F. Murrell
-
Patent number: 10358448Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.Type: GrantFiled: July 24, 2018Date of Patent: July 23, 2019Assignee: Janssen Pharmaceutica NVInventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
-
Patent number: 10307452Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; lemon oil; grapefruit oil; tangerine oil; mandarin oil; lime oil; bergamot oil; petitgrain essential oil; and other citrus oils; meadowfoam seed oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; one or more terpenes and/or terpenoids; and a preservative, such as benzalkonium chloride and vitamin E.Type: GrantFiled: April 16, 2018Date of Patent: June 4, 2019Assignee: GLOBAL LIFE TECHNOLOGIES CORP.Inventor: John A. Willimann
-
Patent number: 10258565Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.Type: GrantFiled: December 21, 2017Date of Patent: April 16, 2019Assignees: ABRAXIS BIOSCIENCE, LLC, MERCATOR MEDSYSTEMS, INC.Inventors: Kirk Seward, Neil P. Desai
-
Patent number: 10207988Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.Type: GrantFiled: March 13, 2013Date of Patent: February 19, 2019Assignee: THE JACKSON LABORATORYInventors: Kevin David Mills, Muneer Gulamhusien Hasham, Caroline Gardner McPhee
-
Patent number: 10201533Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.Type: GrantFiled: October 5, 2017Date of Patent: February 12, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Tao Yu, Yonglian Zhang, Sherman Tim Waddell, John M. Sanders, Thomas H. Graham, Hong Li
-
Patent number: 10166190Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.Type: GrantFiled: January 13, 2017Date of Patent: January 1, 2019Assignee: VELOXIS PHARMACEUTICALS A/SInventors: Nikolaj Skak, Per Holm
-
Patent number: 10143682Abstract: A medicine for improving the state of pregnancy, which comprises a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; and a use of the medicine.Type: GrantFiled: October 28, 2015Date of Patent: December 4, 2018Assignee: KOUSHI YAMAGUCHIInventor: Koushi Yamaguchi
-
Patent number: 10123996Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.Type: GrantFiled: June 13, 2016Date of Patent: November 13, 2018Assignee: Elixir Medical CorporationInventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
-
Patent number: 10039839Abstract: The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.Type: GrantFiled: January 8, 2016Date of Patent: August 7, 2018Assignee: Warp Drive Bio, Inc.Inventors: Gregory Lawrence Verdine, Matthew James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
-
Patent number: 9987260Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.Type: GrantFiled: July 28, 2017Date of Patent: June 5, 2018Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
-
Patent number: 9974796Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.Type: GrantFiled: July 18, 2016Date of Patent: May 22, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Sanjay A. Desai, Ajay D. Pillai